SCHEMBL1443564

SCHEMBL1443564

CC(=O)OC(O)C(O)CO

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.42
CHRM2 P08172 1/20 0.37
CHRM4 P08173 1/20 0.37
CHRM1 P11229 1/20 0.37
TBXA2R P21731 1/20 0.37
GALR3 O60755 1/20 0.35
MAPT P10636 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
LMNA P02545 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE4A P27815 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
PRKCA P17252 2/20 0.33
ALOX15 P16050 1/20 0.33
USP2 O75604 1/20 0.32
SLCO1B1 Q9Y6L6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28404010 0.86 LMNA (0.43) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL347296 0.82 TDP1 (0.50) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL349281 0.82 TDP1 (0.50) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL28363638 0.81 PDE4A (0.32) LMNAL3MBTL1PDE4ATDP1USP2
SCHEMBL7776197 0.80 TSHR (0.42) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL18880921 0.80 TDP1 (0.43) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL11472471 0.78 TDP1 (0.42) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL13687836 0.78 TDP1 (0.42) TSHRCHRM2CHRM4CHRM1TBXA2R
SCHEMBL11710808 0.78 TSHR (0.41) TSHRPDE4A
SCHEMBL396999 0.76 TSHR (0.39) TSHRCHRM2CHRM4CHRM1TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3417724-B1 METHOD FOR PROCESSING HEAT-NOT-BURN CIGARETTES GUANGDONG GOLDEN LEAF TECH DEVELOPMENT CO LTD (CN) 2024-12-04 EP claimed
EP-2627708-B1 DISPERSANT CONTAINING GYPSUM SLURRY BASF CONSTRUCTION POLYMERS GMBH (DE) 2020-05-13 EP claimed
EP-2473457-B1 FORMULATION AND ITS USE BASF CONSTR POLYMERS GMBH (DE) 2014-10-08 EP claimed
US-20130330532-A1 DISPERSANT CONTAINING GYPSUM SLURRY BASF CONSTRUCTION POLYMERS GMBH (DE) 2013-12-12 US claimed
EP-2627708-A2 DISPERSANT CONTAINING GYPSUM SLURRY BASF Construction Polymers GmbH (DE) 2013-08-21 EP claimed
US-20130005861-A1 FORMULATION AND ITS USE DIERSCHKE FRANK (DE) 2013-01-03 US claimed
US-20120308840-A1 FORMULATION AND USE THEREOF BASF SE (DE) 2012-12-06 US claimed
EP-2473457-A1 FORMULATION AND ITS USE BASF Construction Polymers GmbH (DE) 2012-07-11 EP claimed
WO-2012049077-A2 DISPERSANT CONTAINING GYPSUM SLURRY BASF CONSTRUCTION POLYMERS GMBH (DE) 2012-04-19 WO claimed
WO-2011029711-A1 FORMULATION AND ITS USE BASF CONSTRUCTION POLYMERS GMBH (DE) 2011-03-17 WO claimed
US-20110054081-A1 FORMULATION AND ITS USE BASF CONSTRUCTION POLYMERS GMBH (DE) 2011-03-03 US claimed
WO-2026099480-A1 NONWOVEN FABRIC AND ITS USE FOR ORAL DOSAGE FORMS CARL FREUDENBERG KG (DE) 2026-05-15 WO disclosed
EP-4740754-A1 NONWOVEN FABRIC AND ITS USE FOR ORAL DOSAGE FORMS Carl Freudenberg KG (DE) 2026-05-13 EP disclosed
EP-4335466-A1 COMPOSITION FOR THE PREPARATION OF A BONE SUBSTITUTE MATERIAL, METHOD FOR THE PREPARATION OF A PHARMACEUTICAL ACTIVE SUBSTANCE CARRIER, PHARMACEUTICAL ACTIVE SUBSTANCE CARRIER AND ITS USE Heraeus Medical GmbH (DE) 2024-03-13 EP disclosed
EP-3798276-B1 AQUEOUS PAINT COMPOSITION ARCOLOR AG (CH) 2023-06-07 EP disclosed
WO-2012049077-A2 DISPERSANT CONTAINING GYPSUM SLURRY BASF CONSTRUCTION POLYMERS GMBH (DE) 2012-04-19 WO disclosed
WO-2011029711-A1 FORMULATION AND ITS USE BASF CONSTRUCTION POLYMERS GMBH (DE) 2011-03-17 WO disclosed
WO-2011028817-A1 ADDITIVES IN GYPSUM PANELS AND ADJUSTING THEIR PROPORTIONS UNITED STATES GYPSUM COMPANY (US) 2011-03-10 WO disclosed
US-20110054081-A1 FORMULATION AND ITS USE BASF CONSTRUCTION POLYMERS GMBH (DE) 2011-03-03 US disclosed
US-20110054053-A1 ADDITIVES IN GYPSUM PANELS AND ADJUSTING THEIR PROPORTIONS UNITED STATES GYPSUM COMPANY 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120308840-A1 FORMULATION AND USE THEREOF SMCHD1, SMS, PEF1 TSHR 4692/4885CHRM2 1389/4885CHRM4 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.